

## RESEARCH

### BOB ECONOMICS RESEARCH | INR AND INFLATION

INR depreciation and its impact on inflation

### BOB ECONOMICS RESEARCH | RBI MONETARY POLICY

RBI surprises with a cut

### EMCURE PHARMA | TARGET: Rs 1,656 | +19% | BUY

Margin increment to increase return ratios

## SUMMARY

### INDIA ECONOMICS: INR AND INFLATION

INR has depreciated sharply in the last few days, crossing several key psychological levels. It closed at 90.19/\$ on 3 Dec 2025, touching a record historic low. There was a recovery subsequently on 4th. There have been several reasons contributing to this fall including strong demand from importers, slowdown in foreign inflows, high trade deficit and uncertainty over US trade deal. INR's depreciation has led to a lot of talk about the likely impact on the economy. Particularly, market participants remain wary of the impact of depreciation on inflation. Our analysis shows that a 5% depreciation in INR is likely to push up inflation by ~15-25bps on an annualized basis, with gold, edible oils and pulses likely to see the major impact.

[Click here](#) for the full report.

### INDIA ECONOMICS: RBI MONETARY POLICY

The MPC unanimously decided to cut its policy repo rate by 25bps to 5.25%, after keeping it steady at each of its last two meetings. Stance of the monetary policy was retained at neutral, with one member favouring an accommodative stance. RBI also announced OMO auctions and USD/INR buy sell swap auction to inject durable liquidity into the system. These measures are likely to infuse additional liquidity of Rs. 1.45 lakh crores in the system. With regard to the MPC's assessment of the growth and inflation outlook, RBI revised its growth projections upwards based on the trends seen so far.

[Click here](#) for the full report.

**BOBCAPS Research**  
research@bobcaps.in



## EMCURE PHARMA

- We hosted Mr. Vikas Thapar (President) and Mr. Piyush Nahar (IR Head) virtually. The duo expressed enthusiasm over Poviztra brand
- Management expects margins to continue rising for the next 1-2 years, driven by no MR hiring and increasing productivity
- Expect Sales/EBITDA/PAT to grow at a CAGR of 12%, 18% and 23% from FY26-28E. Continue to ascribe a PE of 24x on Dec'27 roll forward basis

[Click here](#) for the full report.

## INR AND INFLATION

05 December 2025

### INR depreciation and its impact on inflation

INR has depreciated sharply in the last few days, crossing several key psychological levels. It closed at 90.19/\$ on 3 Dec 2025, touching a record historic low. There was a recovery subsequently on 4th. There have been several reasons contributing to this fall including strong demand from importers, slowdown in foreign inflows, high trade deficit and uncertainty over US trade deal. INR's depreciation has led to a lot of talk about the likely impact on the economy. Particularly, market participants remain wary of the impact of depreciation on inflation. Our analysis shows that a 5% depreciation in INR is likely to push up inflation by ~15-25bps on an annualized basis, with gold, edible oils and pulses likely to see the major impact.

**Aditi Gupta**  
Economist


#### Movement in INR over the years:

The depreciation seen in INR in recent days is not unusual as there has been a tendency for the currency to depreciate historically as well. This is not a unique phenomenon for India only, as exchange rate movements of a majority of developing countries also shows a similar trend. This is due to several factors including high inflation, large trade deficits, limited foreign flows and vulnerabilities to external shocks including financial system and commodity price risks.

Between 2010-2024 (calendar year), on a point-to-point basis, INR has depreciated 13 times, losing about 48% of its value. Even narrowing the range to the last 10 years (Fig 1), there is only a single year i.e 2017, in which the currency appreciated. The average depreciation in INR in the period is 2.9%. However, in 7 out of the 10 years, the actual depreciation was lower than the average. In fact, barring 2018 and 2022, the movement in the exchange rate has largely been within the long-term average trend. Even last year, the currency depreciated by just 2.8%. This was notwithstanding a 7% increase in the value of the dollar.

This year the situation is quite different. INR has depreciated by over 5% since 31 Dec 2024, even as the dollar has weakened. In fact, the DXY index has declined by ~9% since the start of the year.

**Fig 1: Currency depreciation over the years**



Source: Bloomberg, Bank of Baroda Research | Note: \*Data upto 3 Dec 2025



## RBI MONETARY POLICY

05 December 2025

### RBI surprises with a cut

The MPC unanimously decided to cut its policy repo rate by 25bps to 5.25%, after keeping it steady at each of its last two meetings. Stance of the monetary policy was retained at neutral, with one member favouring an accommodative stance. RBI also announced OMO auctions and USD/INR buy sell swap auction to inject durable liquidity into the system. These measures are likely to infuse additional liquidity of Rs. 1.45 lakh crores in the system. With regard to the MPC's assessment of the growth and inflation outlook, RBI revised its growth projections upwards based on the trends seen so far.

**Aditi Gupta**  
Economist

At the same time, inflation projections received a significant downward revision. With this, growth in FY26 is estimated at 7.3% compared with 6.8% estimated earlier. Inflation is projected at 2.0% marking a downward revision of 60bps. More importantly, while the RBI sees some risks to the growth outlook from trade related uncertainties, it remains confident on the inflation trajectory. This makes us revisit our base scenario of the terminal rate settling at 5.25%. We now believe that there is a high probability of a further cut of 25bps in Feb'26, which will mark an end to its rate cut cycle.

#### MPC decision:

RBI's monetary policy committee (MPC) voted unanimously to reduce the policy repo rate by 25bps to 5.25%. This was the first rate cut since Jun'25, when the policy rate was reduced by 50bps. The MPC also continued with the neutral stance, even though one MPC member, i.e. Prof. Ram Singh favoured changing the stance to accommodative.

#### Assessment of growth and inflation outlook:

- RBI revised its growth projection upwards by 50bps to 7.3%. Growth estimates for both Q3 and Q4 were revised higher to 7% (+60bps) and 6.5% (+30bps) respectively. For Q1 FY27 as well, growth is now projected higher at 6.7%, reflecting an upward revision of 30bps.
- For Q2FY27, GDP growth is estimated at 6.8%.
- As per RBI's assessment, benefits from income tax rationalization and GST rate cuts have supported growth in H1 FY26. At the same time, high frequency indicators suggest that economic activity held ground in Q3 FY26, even though there are pockets of stress.



**BUY****TP: Rs 1,656 | ▲ 19%****EMCURE PHARMA**

| Pharmaceuticals

| 05 December 2025

## Margin increment to increase return ratios

- We hosted Mr. Vikas Thapar (President) and Mr. Piyush Nahar (IR Head) virtually. The duo expressed enthusiasm over Poviztra brand
- Management expects margins to continue rising for the next 1-2 years, driven by no MR hiring and increasing productivity
- Expect Sales/EBITDA/PAT to grow at a CAGR of 12%, 18% and 23% from FY26-28E. Continue to ascribe a PE of 24x on Dec'27 roll forward basis

Foram Parekh  
 Research Analyst  
[research@bobcaps.in](mailto:research@bobcaps.in)

**Intends to ramp up Chronic portfolio in domestic region** – Emcure's flagship brand Orofer xt, which is used for iron deficiency classified under Gynaecology, falls under the acute segment. The company ranks 13<sup>th</sup> in the IPM. Therapeutically, it ranked 9<sup>th</sup> in the Cardia segment, however, post the integration of Sanofi's Cardiac portfolio (~Rs 5bn sales), Emcure ranks 4<sup>th</sup> in the Cardiac segment. The company recently acquired Sanofi's Diabetes portfolio (~Rs 1.7bn sales) to get access to the Diabetes therapy. The in-licensed Sanofi's portfolio as well as the newly in-licensed Novo's portfolio to likely enable expanding presence in the Chronic segment (38% as on 2QFY26) and have a rub-off effect on the base portfolio.

**Poviztra to garner wider acceptance** – Management expressed confidence in a wider acceptance of Semaglutide over Tirzepatide, given that Sema is approved for three indications (Weight loss, Cardio and MASH indication). The innovator aims to increase market share as the competition is expected to intensify post LOE (Mar'26), thus introducing the 2<sup>nd</sup> brand of Semaglutide. Pharma MNCs anticipate the Obesity category to be an opportunity for 20 years; hence partly, the innovator would shape the market and partly Emcure's 5400 MRs are likely to deepen penetration in the domestic region.

**Non-ARV pie in ROW segment to grow bigger** – Currently, within the ROW region, ARV- Non-ARV is 50-50. Non-ARV segment has a healthy pipeline of differentiated products in the complex injectables and biosimilars with a TAM of USD2bn. The key launch being Amphotericin B with TAM of USD 300mn and 2 player market for the next two years, hoping to easily achieve market share of ~20% plus.

**Pan Europe Amphotericin B launch to drive Europe growth** – Emcure launched Amphotericin B injectable in the UK and Italy and intends to launch in Pan Europe as well. The company expects it to be a two-player market in Europe too with TAM of USD 300 mn. Emcure anticipates to garner 20% market share in Europe too as the product is less competitive. There are also a couple of complex injectables like Ferric Carboxy Maltose and Doxorubicin which has a TAM of USD 1bn sales. Emcure's Manx portfolio has given access to 120+ MA, doubles the current portfolio in UK and has a strong product pipeline of 55+ products.

## Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	EMCURE IN/Rs 1,396
Market cap	US\$ 2.9bn
Free float	22%
3M ADV	US\$ 3.0mn
52wk high/low	Rs 1,520/Rs 889
Promoter/FPI/DII	78%/3%/3%


Source: NSE | Price as of 5 Dec 2025

## Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	78,960	89,193	100,725
EBITDA (Rs mn)	14,689	17,306	20,290
Adj. net profit (Rs mn)	6,917	9,101	11,044
Adj. EPS (Rs)	36.5	48.0	58.3
Consensus EPS (Rs)	36.7	49.4	59.7
Adj. ROAE (%)	18.7	20.8	25.4
Adj. P/E (x)	38.2	29.1	24.0
EV/EBITDA (x)	16.6	14.4	12.2
Adj. EPS growth (%)	30.1	31.6	21.4

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE



**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.